METTL3 and breast cancer: Interestingly, contrasting viewpoints have been put forward, suggesting that knocking down METTL3 in HR+/HER2− BC cells can lead to the modulation of CDKN1A/EMT and m6A-bax/caspase-9/-3/-8 signaling pathways.